Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. (ATRA) on March 31, 2023. The report discloses a material corporate governance event regarding the departure of a senior executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
The primary material change reported is the resignation of Utpal Koppikar, Executive Vice President and Chief Financial Officer, effective March 31, 2023. Following his resignation, Mr. Koppikar entered into a six-month consulting agreement with the Company.
Management Commentary and Compensation Details
- Consulting Role: Mr. Koppikar will provide consulting services for a six-month term.
- Compensation: He will receive a monthly consulting fee of $2,800 for a specified number of hours, plus an additional $175 per hour for any excess hours.
- Equity: Outstanding equity awards will continue to vest during the consulting term.
Investor Verification Checklist
- Verify the appointment of an interim or permanent replacement for the Chief Financial Officer role.
- Review the Company's subsequent filings for any impact on financial reporting timelines or internal controls due to the CFO transition.
- Confirm the total estimated cost of the consulting agreement against the Company's current cash position.